Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DO40BQ
|
|||
| Drug Name |
mRNA-3745
|
|||
| Drug Type |
mRNA therapy
|
|||
| Indication | Glycogen storage disease type IA [ICD-11: 5C51.3] | Phase 1 | [1] | |
| Company |
Moderna
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Glucose-6-phosphatase catalytic subunit 1 messenger RNA (G6PC1 mRNA) | Target Info | . | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT05095727) A Phase 1/2, Adaptive, Open-label, Single Ascending Dose to Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of mRNA-3745 in Participants With Glycogen Storage Disease Type 1a (GSD1a), Followed by an Open-label Extension. U.S.National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of Moderna | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.